Verastem, Inc. current report, 21 November 2012

Verastem, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Verastem, Inc. on November 21, 2012, covering events occurring between November 21 and November 26, 2012. The filing addresses changes to the composition of the Company's Board of Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

  • Resignations: Stephen Kraus resigned from the Board of Directors effective November 21, 2012. Ansbert Gadicke, M.D., resigned effective November 26, 2012. Both resignations were accepted by the Board and were not the result of disagreement or removal for cause.
  • Elections: On November 26, 2012, the Board unanimously elected Alison Lawton and Michael Kauffman, M.D., Ph.D., as new directors.
  • Committee Assignments: Ms. Lawton is expected to serve on the Nominating and Corporate Governance Committee. Mr. Kauffman is expected to serve on the Compensation Committee.

Compensatory Arrangements and Outlook

In connection with their election, Ms. Lawton and Mr. Kauffman each received an initial stock option grant for 25,000 shares of common stock. Under the Company's director compensation policy, they are eligible for annual cash retainer fees and an annual stock option grant of 12,500 shares. Both directors entered into customary indemnification agreements. The filing does not provide specific guidance, risk factors, or management commentary regarding the Company's future business outlook.

Investor Verification Checklist

  • Verify the qualifications and backgrounds of the new directors, Alison Lawton and Michael Kauffman, as detailed in the accompanying press release (Exhibit 99.1).
  • Confirm the impact of the board changes on the composition of the Nominating, Corporate Governance, and Compensation Committees.
  • Review the Company's most recent 10-K or 10-Q filings for financial metrics, as this 8-K does not contain financial data.